Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesA phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer
Journal of Thoracic Oncology, 09/04/09
Binder D et al. – Weekly docetaxel-cisplatin demonstrated comparable efficacy with three-weekly schedules.
Methods- Patients with inoperable stage International Union Against Cancer IIIB (malignant effusion) or IV non-small cell lung cancer received docetaxel (35 mg/m2, 30 minutes infusion) and cisplatin (25 mg/m2, 30 minutes infusion) on days 1, 8, and 15, every 4 weeks for 4 to 6 cycles
- Ondansetron (8 mg) and dexamethasone (8 mg) were given intravenously before chemotherapy
- Twelve of 44 patients achieved an objective response (11 partial, 1 complete, intent-to-treat response rate 27%).
- Median TTP was 4.4 months
- Median survival 9.6 months
- Patients received a median of three full cycles
- Four patients (9%) required dose reductions
Related Articles
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Relevance Score: 93%
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 91%
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Relevance Score: 89%
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/09
Relevance Score: 88%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 12/04/09
Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD: a systematic review and meta-analysis
European Respiratory Journal , 12/03/09
Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis
Journal of Cystic Fibrosis , 12/02/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 12/04/09
Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904
Journal of Clinical Oncology, 12/04/09
Nutrition Aspects of Lung Cancer
Nutrition in Clinical Practice, 12/03/09
Sponsor
Article Search
Sponsor